4.7 Article

A dual chicken IgY against rotavirus and norovirus

Journal

ANTIVIRAL RESEARCH
Volume 97, Issue 3, Pages 293-300

Publisher

ELSEVIER
DOI: 10.1016/j.antiviral.2012.12.011

Keywords

Rotavirus; Norovirus; Diarrhea; Immunoglobulin Y (IgY); Passive immunization

Funding

  1. National Institute of Health of the United States [R01 AI 055649, R01 AI 37093, R01 AI 089634, P01 HD 13021]
  2. Agriculture and Food Research Initiative Competitive Grants Program of the USDA National Institute of Food and Agriculture, NIFA Award [2011-68003-30005]
  3. Guangdong Province '211 Project'
  4. School of Public Health and Tropical Medicine of Southern Medical University [GW201233]
  5. National Natural Science Foundation of China [30901992]

Ask authors/readers for more resources

Rotavirus (RV) and norovirus (NoV) are the two most important causes of viral gastroenteritis. While vaccine remains an effective prophylactic strategy, development of other approaches, such as passive immunization to control and treat clinical infection and illness of these two pathogens, is necessary. Previously we demonstrated that high titers of NoV-specific IgY were readily developed by immunization of chickens with the NoV P particles. In this study, we developed a dual IgY against both RV and NoV through immunization of chickens with a divalent vaccine comprising neutralizing antigens of both RV and NoV. This divalent vaccine., named P-VP8* particle, is made of the NoV P particle as a carrier with the RV spike protein VP8* as a surface insertion. Approximately 45 mg of IgY were readily obtained from each yolk with high titers of anti-P particle and anti-VP8* antibodies detected by ELISA, Western blot, HBGA blocking (NOV and RV) and neutralization (RV). assays. Reductions of RV replication were observed with viruses treated with the IgY before and after inoculation into cells, suggesting an application of the IgY as both prophylactic and therapeutic treatment. Collectively, our data suggested that the P-VP8* based IgY could serve as a practical approach against both NoV and RV. (C) 2012 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available